iBio, Inc. Announces Promising Preclinical Results for IBIO-610 in Obese Non-Human Primates

Key Highlights

• iBio, Inc. (NASDAQ: IBIO) reports new preclinical data for its antibody candidate IBIO-610 targeting obesity and related diseases.
• The study in obese non-human primates (NHPs) demonstrated fat-selective weight loss with a reduction of 6.7% visceral fat and 5.2% total fat mass after two doses, despite a continued high-calorie diet.
• IBIO-610 caused only a slight increase in lean mass, suggesting a targeted fat loss profile while preserving muscle.
• Results align with prior rodent studies and human clinical trials involving the Activin E pathway, supporting IBIO-610’s differentiation as a therapy.
• The antibody candidate exhibited an extended half-life of 33.2 days in NHPs and is projected to have a human half-life of up to 100 days, potentially enabling convenient twice-yearly dosing.
• Further biomarker analysis is underway, with full results to be presented at scientific conferences throughout 2026.

Details for Shareholders

• Potential Market Impact: The fat-selective nature of IBIO-610 and its extended dosing interval could position it as a first-in-class therapy for obesity and cardiometabolic diseases, distinguishing it from existing treatments.
• AI-Driven Discovery: iBio is leveraging artificial intelligence and advanced computational biology to accelerate drug discovery and development, aiming to create novel antibody treatments for hard-to-treat diseases.
• Pipeline Expansion: The company’s proprietary 3D modeling and discovery platforms are intended to address significant unmet medical needs, with IBIO-610 being a key candidate.
• Regulatory Path: While the results are promising, shareholders should be aware that these are preclinical findings from a small, non-statistically powered study. The candidate has not yet advanced to human clinical trials, and regulatory approval will be required before commercialization.
• Risks & Forward-Looking Statements: The company notes that forward-looking statements are subject to risks, including but not limited to: success in clinical trials, regulatory approval processes, market acceptance, and unforeseen liabilities or expenses.

Management Commentary

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer:
“These data reinforce IBIO-610’s potential to deliver fat-selective improvements in body composition while maintaining lean mass. When added to the previously demonstrated extended half-life, these results further confirm the potential of IBIO-610 as a first-in-class therapy, and the capability of our AI-enabled discovery platform to address complex targets in obesity, cardiometabolic and cardiopulmonary diseases, and may significantly improve the lives of patients.”

Cory Schwartz, Ph.D., Director of Research and Early Development:
“We believe IBIO-610’s fat-selective biology supports its potential to drive targeted fat loss while maintaining lean mass. Our team is continuing its thorough analyses of the dataset spanning metabolic, biomarker, and mechanistic endpoints, and we look forward to presenting additional insights.”

What Shareholders Should Watch

• Upcoming scientific presentations of the full dataset in 2026, including biomarker and mechanistic analyses.
• Progress toward human clinical trials for IBIO-610.
• Regulatory developments and potential commercialization timelines for IBIO-610 and other candidates in iBio’s pipeline.
• Continued advancements in AI-driven drug discovery and the impact on iBio’s competitive position.

Contact Information

Corporate Contact:
iBio, Inc.
Investor Relations: [email protected]
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604

Disclaimer

This article contains forward-looking statements based on information currently available and management’s estimates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should not place undue reliance on these statements and are encouraged to review the company’s filings with the SEC for additional risk factors. The information provided is for informational purposes only and does not constitute investment advice.

View iBio, Inc. Historical chart here